Advertisement
Screener

FOXO TECHNOLOGIES INC. (FOXO) EBITDA

FOXO TECHNOLOGIES INC. (FOXO) EBITDA

  • 2026-06-30: Basis Reported; EBITDA $8.92M*; Operating income $8.75M; Depreciation and amortization $175.79K*.
  • 2026-03-31: Basis Reported; EBITDA -$105,757.00; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$8.33M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$716.62K*; Operating income -$859.82K; Depreciation and amortization $143.20K*.

Complete source-backed ebitda history.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported$8.92M*$8.75M$175.79K*$4.72M189.27%*$5.38K*$298.67K*(m)$23.70K$2.68M(m)
2026-03-31Reported-$105,757.00(m)(m)(m)-2.05%$4.00K-$577.90K(m)$35.55K$2.88M(m)
2025-12-31Reported-$8.33M(m)(m)(m)-187.88%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$716.62K*-$859.82K$143.20K*$3.55M-20.20%*(m)-$44.78K*(m)$77.10K$2.47M(m)
2025-06-30Reported$713.89K*$567.12K$146.77K*$5.22M13.68%*(m)-$2.38M*(m)$40.18K$2.62M(m)
2025-03-31Reported-$1.4M(m)(m)(m)-44.29%(m)-$1.34M(m)$30.00K$2.76M(m)
2024-12-31Reported-$3.55M(m)(m)(m)-125.86%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$730.82K*-$1.01M$274.48K*$1.20M-61.08%*(m)$577.18K*(m)$43.81K$1.73M(m)
2024-06-30Reported-$1.54M(m)(m)(m)-5596.45%(m)-$1.17M*(m)$103.10K$1.47M(m)
2024-03-31Reported-$918,344.00(m)(m)(m)-12790.31%(m)-$406.30K(m)$165.36K$987.94K(m)
2023-12-31Reported-$3.66M(m)(m)(m)-3314.60%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$3.43M*-$3.51M$75.00K*$10.00K-34320.00%*(m)-$865.00K*(m)$283.00K$4.72M(m)
2023-06-30Reported-$7.36M(m)(m)(m)-61316.67%(m)-$1.94M*(m)$333.00K$4.00M(m)
2023-03-31Reported-$6.46M(m)(m)(m)-49715.38%(m)-$3.36M(m)$309.00K$6.33M(m)
2022-12-31Reported-$19.53M(m)(m)(m)-4672.97%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$8.74M*-$8.81M$73.00K*(m)(m)(m)-$5.04M*(m)$558.00K$8.27M(m)
2022-06-30Reported(m)-$5.93M(m)(m)(m)(m)-$7.00M*(m)$1.00M$4.97M(m)
2022-03-31Reported(m)-$4.56M(m)(m)(m)(m)-$7.19M(m)$601.00K$4.00M(m)
2021-12-31Reported(m)-$1.30M(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30Reported(m)-$4.36M(m)(m)(m)(m)-$11.49M*(m)$1.67M$2.72M(m)
2021-06-30Reported(m)-$203.12K(m)(m)(m)(m)-$139.16K*(m)(m)(m)(m)
2021-03-31Reported(m)-$213.61K(m)(m)(m)(m)-$114.23K(m)(m)(m)(m)
2020-12-31Reported(m)-$1.15M(m)(m)(m)(m)(m)(m)(m)(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$9.73M(m)(m)(m)-59.46%$62.02K-$3.87M(m)$182.50K$11.36M-$182.83K
2024-12-31Reported-$6.53M(m)(m)(m)-161.09%(m)-$2.84M(m)$312.27K$7.23M(m)
2023-12-31Reported-$20.91M(m)(m)(m)-14390.92%(m)-$6.65M(m)$900.43K$19.40M(m)
2022-12-31Reported-$38.68M(m)(m)(m)-7569.47%$110.00K-$23.76M$344.00K$3.05M$25.83M(m)
2022-09-30Rolling(m)-$20.61M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-06-30Rolling(m)-$16.15M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-03-31Rolling(m)-$10.42M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-12-31Reported(m)-$15.03M(m)(m)(m)$118.00K-$15.05M(m)$4.88M$10.27M(m)
2021-12-31Rolling(m)-$6.07M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30Rolling(m)-$5.92M*(m)(m)(m)(m)(m)(m)(m)(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
iSpecimen Inc. (ISPC)United States$0.003B
OneMedNet Corp (ONMD)$0.042B
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14